Kaushik, Ankita
Dusheiko, Geoffrey
Kim, Chong
Smith, Nathaniel J.
Kinyik-Merena, Csilla
Di Tanna, Gian Luca
Wong, Robert J.
Funding for this research was provided by:
Gilead Sciences
Article History
Accepted: 10 December 2023
First Online: 3 January 2024
Declarations
:
: This study was supported by Gilead Sciences.
: Ankita Kaushik and Chong Kim are employees and stockholders of Gilead. Robert J. Wong has received consulting fees for Gilead Sciences, and research grants (in kind) from Gilead Sciences. George Dusheiko has received consulting fees and speaker fees from Gilead Sciences; has participated on the Data Safety Monitoring Board/Advisory Board for Janssen, Glaxo Smith Kline, Arbutus, Aligos, Vir; and has roles in the National Medical Research Council Singapore and the World Health Organization Pediatric Working Group on Viral Hepatitis. A honorary fee has been paid from Gilead to The George Institute for methodological support provided by Gian Luca di Tanna. Nathaniel J. Smith and Csilla Kinyik-Merena have no financial disclosures to declare.
: The data generated to inform the economic model are not publicly available but may be available from the corresponding author on reasonable request.
: Not applicable.
: Not applicable.
: All authors participated in the conceptualization, methodology and validation of the model. NJS and CKM participated in the data analysis. AK and CK participated in the investigation and data curation. NJS and CKM developed the model manuscript. All authors participated in the reviewing and editing of the manuscript, and approved the final version of the manuscript submitted for publication.
: Not applicable.
: Not applicable.